Abstract
BCR/ABL translocation is the major cause of Chronic Myelogenous Leukemia (CML) and basic research to understand its pathogenesis is still on going. Current treatment for CML caused by BCR/ABL is Imatinib Mesylate (Glivec) and it has proven a great success. However it has been well documented that BCR/ABL adapts to the drug and necessitate finding better targets to prevent the disease. In this paper our tactic was to use TEL/ABL translocation to approach CML from a different perspective in the hopes of learning more about BCR/ABL and TEL/ABL pathogenesis. This translocation induces either CML with a late onset or an interesting case of small bowel disease. We tried to use a new method to decrease the over expression of TEL/ABL long form and observe its results in terms of small bowel syndrome and late onset CML.